Faulty Statistics Muddy fMRI Results

An analysis of the widely used technique calls into question the validity of 40,000 studies.

Written byTanya Lewis
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

fMRI during working memory taskWIKIMEDIAFunctional magnetic resonance imaging (fMRI) is widely used in neuroscience. But according to a recent analysis by researchers from Massachusetts General Hospital in Boston, one of the most commonly used software packages for fMRI data generates false-positive rates as high as 70 percent. The analysis calls some 40,000 studies into question, the researchers reported last week (June 28) in PNAS.

“Though fMRI is 25 years old, surprisingly its most common statistical methods have not been validated using real data,” study coauthor Anders Eklund of Linköping University, in Sweden, told Wired.

The imaging method divides the brain up into small units called voxels, in which brain activity is measured. Then the software sorts through these voxels and looks for “clusters” with similar activity.

Eklund and colleagues compiled publicly available resting-state fMRI data from nearly 500 healthy controls. The researchers randomly assigned some of the subjects to a control group and others to an “experimental” group. Then they fed the data into one of three commonly used software packages (SPM, FSL, and AFNI) thousands of times, Ars Technica reported.

In addition to finding a startlingly high false-positive ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies